Naltrexone long acting formulations and methods of use

Details Naltrexone long acting formulations and methods of use Naltrexone long acting formulations and methods of use

2011-04-05

2011-04-05

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S171000, C424S422000

Reexamination Certificate

active

07919499

ABSTRACT:
The inventions described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes a method for treating an individual in need of naltrexone comprising the step of parenterally administering a long acting formulation comprising naltrexone and to the use of naltrexone in the manufacture of medicaments for use in such methods.

REFERENCES:
patent: 4719219 (1988-01-01), Arvidsson et al.
patent: 4882335 (1989-11-01), Sinclair
patent: 5407609 (1995-04-01), Tice et al.
patent: 5512593 (1996-04-01), Dante
patent: 5654008 (1997-08-01), Herbert et al.
patent: 5792477 (1998-08-01), Rickey et al.
patent: 6143314 (2000-11-01), Chandrashekar et al.
patent: 6264987 (2001-07-01), Wright et al.
patent: 6306425 (2001-10-01), Tice et al.
patent: 6358443 (2002-03-01), Herbert et al.
patent: 6495155 (2002-12-01), Tice et al.
patent: 2004/0151774 (2004-08-01), Pauletti et al.
patent: 01/15699 (2001-03-01), None
patent: 01/43726 (2001-06-01), None
patent: WO 2004/064752 (2004-08-01), None
patent: WO 2004/108084 (2004-12-01), None
O'Malley, Stephanie S. et al., “Initial and Maintenance Naltrexone Treatment for Alcohol Dependence Using Primary Care vs Specialty Care. A Nested Sequence of 3 Randomized Trials,” Arch Intern Med., 163: 1695-1704 (2003).
Latt, Noeline C. et al., “Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting,” MJA, 176: 530-534 (2002).
Heinala, Pekka et al., “Targeted Use of Naltrexone Without Prior Detoxification in the Treatment of Alcohol Dependence: A Factorial Double-Blind, Placebo-Controlled Trial,” J Clinical Psychopharmacology, 21(3):287-292 (2001).
“Evidence for the Efficacy of Naltrexone in the Treatment of Alcohol Dependence (Alcoholism),” Addiction Treatment Forum, Ed., Leavitt, Stewart, pp. 1-8 (2002).
Reuning, R.H., et al., “Pharmacokinetic quantitation of naltrexone release from several sustained-released delivery,” NIDA, Research Monograph, Institute on Drug Abuse, 28:172-184, (1981).
Yolles, S., et al., “Long acting delivery for narcotic antagonists II: release reates of naltrexone from Poly(lactic acid) composites,” PDA J. of Pharm. Sci and Tech., 64(2):348-349, (1995).
Bartus, et al., Vivitrex®, an Injectable, Extended-Release Formulation of Naltrexone, Provides Pharmacokinetic and Pharmacodynamic Evidence of Efficacy for 1 Month in Rats,Neuropsychopharmacology, 28:1973-1982 (Aug. 2003).
Comer, Sandra D. et al., “Depot Naltrexone: Long-lasting Antagonism of the Effects of Heroin in Humans,” Psychopharmacology, 159:351-360 (2002).
Chiang, C.N. et al., “Kinetics of a Naltrexone Sustained-release Preparation,” Clinical Pharmacology and Therapeutics, 36(5): 704-708.
U.S. Appl. No. 60/554,658, filed Mar. 19, 2004, Elliott Ehrich, et al.
U.S. Appl. No. 60/554,785, filed Mar. 19, 2004, Elliott Ehrich, et al.
U.S. Appl. No. 11/082,420, filed Mar. 17, 2005, Elliott Ehrich, et al.
U.S. Appl. No. 11/082,534, filed Mar. 17, 2005, Elliott Ehrich, et al.
Swift, Robert M., “Drug Therapy for Alcohol Dependence,”New England J. of Med., 340(19): 1482-1490 (1999).
Karam-Hage, Maher and Brower, Kirk J., “Gabapentin Treatment for Insomnia Associated With Alcohol Dependence,”Am. J. Psychiatry, 157(1): 151-153 (2000).
Myrick, M.D., Hugh, et al., “Gabapentin Treatment of Alcohol Withdrawal,”Am. J. of Psychiatry, 155(11): 1626-1627, (1998).
Malcolm, M.D., Robert, et al., “Update on Anticonvulsants for the Treatment of Alcohol Withdrawal,”Am. J. on Addictions, 10(1): 16-23, Abstract Only, (2001).
Swift, R., et al., “Naltrexone Effects on Diazepam Intoxication and Pharmacokinetics in Humans,”Psychopharmacology, 135(3): 256-262 (1998), Abstract Only.
Chaves, M.L., et al., “Diazepam Inhibits Retroactive Interference of Memory in Humans: Pretreatment with Naltrexone Does Not Alter This Effect,”Braz. J. Med. Biol. Res., 23(5): 417-421 (1990), Abstract Only.
Fidecka, S. and Langwinski, R., “Effects of Opioid Antagonists on Anticonvulsant and Hypnotic Activity of Benzodiazepines,”Pol. J. Pharmacol., 48(4): 409-414 (1996), Abstract Only.
Longo, L.P., et al., “Divalproex Sodium (Depakote) for Alcohol Withdrawal and Relapse Prevention,”J. Addict Dis., 21(2): 55-64 (2002), Abstract Only.
Minuk, G.Y., et al., “The Use of Sodium Valproate in the Treatment of Alcoholism,”J. Addict Dis., 14(2): 67-74 (1995), Abstract Only.
Reoux, J.P., et al., “Divalproex Sodium in Alcohol Withdrawal: A Randomized Double Blind Placebo-Controlled Clinical Trial,”Alcohol Clin. Exp. Res., 25(9): 1324-1329 (2001), Abstract Only.

Affiliated with

Also associated with

Rating

Naltrexone long acting formulations and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Naltrexone long acting formulations and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Naltrexone long acting formulations and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2660667